About 3BIGS
3BIGS is a Healthcare company based in Suwon (South Korea) founded in 2017. It operates as an a platform for genome-based data analysis is provided. The company has 19 employees. Its chief executive is Park Joon-hyeong. Its Indian entity 3Bigs Omicscore Private Limited reported revenue of ₹4.27 Cr. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Discovery. Its competitors include DNAnexus, Depixus, Seven Bridges Genomics, Ingenuity Systems and BC Platforms and 4 more; 9 of its 9 listed competitors have raised funding.
Company details
3BIGS was founded in 2017 in Suwon-si, South Korea, as a provider in the genomics sector. A platform is offered for analyzing genome sequences to identify variations and specific information. Services include confirmation of gene expression levels through independent experiments and solutions for gene-disease associations. Operations focus on enabling various genomic analyses for research and applications.
- Headquarters Suwon, South Korea
- Employees 19
- SectorsHealthcare
- Phone•••• ••••
- Website 3bigs.com
- Social LinkedIn Facebook
- Legal Name 3Bigs Omicscore Private Limited
- Date of Incorporation 29 May, 2018
- Jurisdiction Bangalore, Karnataka, India
- Annual Revenue₹4.27 Cr
FY 2024 · +22% YoY
- Net Profit₹44.3 Lakh
FY 2024 · 10% margin
- EBITDA₹64.6 Lakh
FY 2024 · 15% margin
- Investors
- Employee Count19
Associated legal entities of 3BIGS
3BIGS operates through 3Bigs Omicscore Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| 3Bigs Omicscore Private Limited CIN U74999KA2018PTC113518 | Active | 29 May 2018 | Bangalore, Karnataka | ₹4.3 Cr | 19 | 2 | View details |
Funding Insights of 3BIGS
- Total Rounds 1
- Investors Count 1
All 1 funding rounds of 3BIGS with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2023 | – | Seed | – | Hancom Care Link | – |
1 investors in total: 1 institutional.
Investors in 3BIGS
3BIGS has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Hancom Care Link.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
An online platform for employee health benefits programs. | 2016 | hcarelink.co.kr | Seoul, South Korea |
Investor details for 3BIGS
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of 3Bigs Omicscore Private Limited (3BIGS)
3Bigs Omicscore Private Limited is the primary company behind 3BIGS. The board of 3Bigs Omicscore Private Limited currently have 2 directors; the longest-serving is Kantharuban Mohan, appointed in 2018. 2 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Kantharuban Mohan DIN 03132384 | Director | 29 May 2018 | 8 yrs 4 mo | 3Bigs Omicscore Private Limited |
| Junhyung Park DIN 08374955 | Director | 08 Mar 2019 | 7 yrs 7 mo | 3Bigs Omicscore Private Limited |
People of 3BIGS
1 people are tracked at 3BIGS (1 in leadership); the tracked headcount is 19.
| Name | Role | Group |
|---|---|---|
Park Joon-hyeong | CEO | Leadership |
Complete people profiles for 3BIGS
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of 3BIGS
Figures of 3Bigs Omicscore Private Limited, the primary company behind 3BIGS, for FY 2024. Revenue was ₹4.27 Cr (+22% year on year). Net profit was ₹44.3 Lakh (10% margin). EBITDA was ₹64.6 Lakh (15% margin). Revenue has grown at a compounded annual rate of +46% over three years and +34% over five years.
- ₹4.27 CrRevenue · FY 2024 · +22% YoY
- ₹44.3 LakhNet profit · 10% margin
- ₹64.6 LakhEBITDA · 15% margin
- ₹25 LakhPaid-up capital
- 19Employees (provident fund records)
- +46%Revenue CAGR, 3 years
- +34%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of 3Bigs Omicscore Private Limited are on its company page.
Detailed financial statements for 3BIGS
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of 3BIGS
2 dated milestones of 3BIGS across 6 years, from founding to its latest funding, stage changes and deals.
- Founded 3BIGS is founded.
- Funding First funding round.
Competitors of 3BIGS
3BIGS has 9 listed competitors in our database, 9 of them funded. They include DNAnexus, Depixus, Seven Bridges Genomics, Ingenuity Systems and BC Platforms, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| dnanexus.com | 2009 | Mountain View, United States | $472.55M | 143 | Cloud-based genome informatics and data management are provided. | |
| depixus.com | 2012 | Paris, France | $34.52M | – | Single-molecule genetic and epigenetic sequencing solutions are provided. | |
| sevenbridges.com | 2009 | Cambridge, United States | $113M | 112 | Cloud-based platform to analyze, store, and act on genomic data. | |
| ingenuity.com | 1998 | Redwood, United States | $20.4M | 30 | Genomic data is analyzed and interpreted via web-based applications. | |
| bcplatforms.com | 1997 | Zurich, Switzerland | $45.44M | 8 | Platforms for genomic data analysis and management are provided. | |
| deepgenomics.com | 2015 | Toronto, Canada | $237.96M | – | Machine learning is utilized for precision medicine and genetic diagnostics. | |
| envisagenics.com | 2014 | Long Island, United States | $46.78M | – | RNA splicing therapeutics are discovered and developed through AI-driven biotechnology. | |
| genomics.com | 2014 | Oxford, United Kingdom | $115.54M | – | Genomic risk assessment and prevention platform is provided. | |
| genomenon.com | 2014 | Ann Arbor, United States | $36.84M | – | AI-based bioinformatics tools and genomic variants meta-database are developed. |
Detailed competitors of 3BIGS
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of 3BIGS
The website of 3BIGS (3bigs.com) receives about 1.1K visits a month.
- Monthly visits1.1K
▲ 407.7% vs previous month
Top companies in Genomics & Gene Therapy Platforms
10 companies that operate in the same segment as 3BIGS (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 562 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about 3BIGS
3BIGS was founded in 2017 and raised its 1st funding round 6 years after it was founded.
3BIGS is headquartered in Suwon, South Korea. It is registered at Suwon, Gyeonggi, South Korea.
Park Joon-hyeong is the current CEO of 3BIGS.
3BIGS has 19 employees.
The primary company behind 3BIGS, 3Bigs Omicscore Private Limited, reported revenue of ₹4.27 Cr for FY 2024, up 22% year on year.
3BIGS was founded in 2017 in Suwon-si, South Korea, as a provider in the genomics sector. A platform is offered for analyzing genome sequences to identify variations and specific information. Services include confirmation of gene expression levels through independent experiments and solutions for gene-disease associations. Operations focus on enabling various genomic analyses for research and applications.
3BIGS's top competitors include DNAnexus, Depixus and Ingenuity Systems.
3BIGS has 1 investor. Key investors include Hancom Care Link.
3BIGS operates through 3Bigs Omicscore Private Limited.
The legal entities of 3BIGS currently have 2 directors, including Kantharuban Mohan, Junhyung Park.